Abstracts tagged "Drug toxicity"

Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 0753 • ACR Convergence 2021
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
John Davelaar¹, Naomi Jessurun², Sander Tas³, Mike Nurmohamed⁴, Bart van den Bemt⁵ and Harald Vonkeman⁶, ¹Netherlands Pharmacovigilance Centre Lareb, Utrecht, Netherlands, ²Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁴Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁶Medisch Spectrum Twente; University of Twente, Enschede, Netherlands
Background/Purpose: Health care professionals tend to focus on adverse drug reactions (ADRs) with the highest clinical impact. Subsequently, ADRs with less obvious clinical impact but…
Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
April Jorge¹, Ronald Melles², Carol Conell³, Na Lu⁴, Michael Marmor⁵, Lucy Young⁶, Natalie McCormick¹, Yuqing Zhang⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, ³Kaiser Permanente Northern California, Palo Alto, CA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
Abstract Number: 1038 • ACR Convergence 2021
Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions
Ghazala Tehseen¹, Alexandra Chadwick², Sarah Wills² and Audrey Low², ¹Faculty of Biology, Medicine and Health. The University of Manchester, Manchester, UK, Manchester, United Kingdom, ²Rheumatology Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Hydroxychloroquine (HCQ) is used to treat rheumatoid arthritis (RA), connective tissue disease (CTD) and other inflammatory conditions. In 2018, the United Kingdom Royal College…
Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Diana Meyler¹, Sofia Pedro², Alan Erickson³, Patricia Katz⁴ and Kaleb Michaud³, ¹UNMC, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1518 • ACR Convergence 2021
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Pankti Reid¹, David Liew², Rajshi Akruwala³, Anne Bass⁴ and Karmela Kim Chan⁵, ¹University of Chicago Medical Center, Chicago, IL, ²Austin Health, Heidelberg, Australia, ³SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 0116 • ACR Convergence 2021
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
Kaleb Michaud¹, Adam Cornish², Alison Freifeld¹, Patricia Katz³ and Kristin Wipfler², ¹University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
Abstract Number: 1642 • ACR Convergence 2021
Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Roberta Berard¹, Michael Rieder², Erkan Demirkaya², Michael Miller³ and Renee Pang², ¹London Health Sciences Centre, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³University of Western Ontario, Children's Research Institute, London, ON, Canada
Background/Purpose: Prednisone is a glucocorticoid (GC) medication commonly used in moderate ( >7.5 mg per day) to high doses (≥ 1 mg/kg/day) for children with…
Abstract Number: 0146 • ACR Convergence 2021
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
Akrithi Udupa¹, Catherine Sims², Poorva Apte², Megan Milne², Isaac Smith¹, D Ryan Anderson¹, Mithu Maheswaranathan², Jayanth Doss² and David Leverenz², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: The COVID-19 pandemic led to the rapid implementation of telehealth in rheumatology with unknown implications for medication toxicity lab monitoring. The purpose of this…
Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 0206 • ACR Convergence 2021
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Alba Herrero-Morant¹, Adrián Margarida-de Castro¹, Raquel Pérez-Barquín², Jon Zubiaur-Zamacola¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].